PROFECT Ionizable: Lipid Nanoparticle for Research: D-Lin-MC3-DMA (MC3)

Regular price
$ 4,800.00
Sale price
$ 4,800.00
Regular price
Sold out
Unit price
per 

 

Nanoparticles were formulated using a microfluidic device as previously described19. Luciferase mRNAs were diluted in

citrate buffer 

PEG-lipids (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]),

cholesterols and helper lipids (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-3-trimethylammonium-propane, 1,2-di-O-octadecenyl-3-trimethylammonium propane dimethyldioctadecylammonium) were diluted in 100% ethanol. 

PEGs, cholesterols, and helper lipids were purchased from Avanti Lipids. Citrate and ethanol phases were combined in a microfluidic device using syringes (Hamilton Company) at a flow rate of 3:1

Lokugamage, M.P., Vanover, D., Beyersdorf, J., Hatit, M.Z., Rotolo, L., Echeverri, E.S., Peck, H.E., Ni, H., Yoon, J.K., Kim, Y. and Santangelo, P.J., 2021. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nature biomedical engineering, 5(9), pp.1059-1068.